Canature Health Technology Co., Ltd. (SHE:300272)
7.59
+0.01 (0.13%)
Feb 11, 2026, 3:04 PM CST
SHE:300272 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,781 | 1,679 | 1,659 | 1,645 | 1,489 | 1,170 |
Other Revenue | 9.16 | 9.16 | 12.51 | 15.67 | 22.71 | 11.02 |
| 1,790 | 1,689 | 1,672 | 1,661 | 1,511 | 1,181 | |
Revenue Growth (YoY) | 6.29% | 1.00% | 0.67% | 9.87% | 27.97% | 12.22% |
Cost of Revenue | 1,105 | 1,041 | 1,056 | 1,112 | 1,010 | 676.73 |
Gross Profit | 685.36 | 647.28 | 615.87 | 548.75 | 501.96 | 504.39 |
Selling, General & Admin | 415.69 | 413.52 | 384.05 | 346.17 | 304.05 | 327.11 |
Research & Development | 69.02 | 67.57 | 65 | 63.94 | 51.49 | 32.63 |
Other Operating Expenses | 4.39 | 5.58 | 5.83 | 9.04 | 3.26 | -7.04 |
Operating Expenses | 489.25 | 486.61 | 457.05 | 419.71 | 361.57 | 353.3 |
Operating Income | 196.11 | 160.67 | 158.82 | 129.04 | 140.39 | 151.09 |
Interest Expense | -35.16 | -34.48 | -28.44 | -16.85 | -16.28 | -15.05 |
Interest & Investment Income | 24.25 | 22.55 | 14.87 | 5.54 | 32.26 | 0.64 |
Currency Exchange Gain (Loss) | 19.75 | 19.75 | 9.58 | 10.12 | 0.84 | -6.75 |
Other Non Operating Income (Expenses) | -11.71 | -5.22 | -4.41 | -9.23 | -5.48 | -12.25 |
EBT Excluding Unusual Items | 193.24 | 163.27 | 150.41 | 118.63 | 151.72 | 117.68 |
Impairment of Goodwill | - | - | - | -15.32 | -5.82 | -21.37 |
Gain (Loss) on Sale of Investments | -52.65 | -33.5 | 4.66 | 2.6 | -2.43 | -55.76 |
Gain (Loss) on Sale of Assets | -0.32 | -0.17 | 2.33 | 1.4 | -0.7 | -0 |
Asset Writedown | 0.21 | - | - | - | -0.19 | -0.08 |
Legal Settlements | -3.73 | -3.73 | -0.24 | - | -3.71 | - |
Other Unusual Items | 9.13 | 9.13 | 1.64 | 6.96 | 6.61 | 25.84 |
Pretax Income | 145.88 | 135 | 158.81 | 114.27 | 145.49 | 66.3 |
Income Tax Expense | 22.63 | 21.56 | 5.33 | 15.24 | 28.39 | 15.78 |
Earnings From Continuing Operations | 123.26 | 113.45 | 153.48 | 99.03 | 117.1 | 50.53 |
Minority Interest in Earnings | -28.49 | -29.87 | -21.03 | -6.47 | -12.24 | -24.11 |
Net Income | 94.76 | 83.58 | 132.45 | 92.56 | 104.86 | 26.42 |
Net Income to Common | 94.76 | 83.58 | 132.45 | 92.56 | 104.86 | 26.42 |
Net Income Growth | 8.56% | -36.90% | 43.09% | -11.73% | 296.93% | -73.72% |
Shares Outstanding (Basic) | 569 | 566 | 562 | 566 | 583 | 528 |
Shares Outstanding (Diluted) | 569 | 579 | 573 | 566 | 583 | 528 |
Shares Change (YoY) | -4.51% | 1.03% | 1.19% | -2.82% | 10.26% | -10.64% |
EPS (Basic) | 0.17 | 0.15 | 0.24 | 0.16 | 0.18 | 0.05 |
EPS (Diluted) | 0.17 | 0.14 | 0.23 | 0.16 | 0.18 | 0.05 |
EPS Growth | 13.68% | -37.54% | 41.41% | -9.17% | 260.00% | -70.59% |
Free Cash Flow | 130.49 | 189.98 | 294.59 | 60.85 | 115.48 | 97.29 |
Free Cash Flow Per Share | 0.23 | 0.33 | 0.51 | 0.11 | 0.20 | 0.18 |
Dividend Per Share | 0.170 | 0.160 | 0.100 | 0.100 | 0.100 | 0.050 |
Dividend Growth | -22.73% | 60.00% | - | - | 100.00% | -50.00% |
Gross Margin | 38.29% | 38.34% | 36.84% | 33.04% | 33.21% | 42.70% |
Operating Margin | 10.96% | 9.52% | 9.50% | 7.77% | 9.29% | 12.79% |
Profit Margin | 5.29% | 4.95% | 7.92% | 5.57% | 6.94% | 2.24% |
Free Cash Flow Margin | 7.29% | 11.25% | 17.62% | 3.66% | 7.64% | 8.24% |
EBITDA | 241.45 | 208.02 | 208.85 | 181.79 | 183.42 | 188.41 |
EBITDA Margin | 13.49% | 12.32% | 12.49% | 10.95% | 12.13% | 15.95% |
D&A For EBITDA | 45.35 | 47.35 | 50.03 | 52.76 | 43.02 | 37.31 |
EBIT | 196.11 | 160.67 | 158.82 | 129.04 | 140.39 | 151.09 |
EBIT Margin | 10.96% | 9.52% | 9.50% | 7.77% | 9.29% | 12.79% |
Effective Tax Rate | 15.51% | 15.97% | 3.36% | 13.34% | 19.51% | 23.79% |
Revenue as Reported | 1,790 | 1,689 | 1,672 | 1,661 | 1,511 | 1,181 |
Advertising Expenses | - | 14.35 | 10.59 | 0.13 | 1.4 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.